Dimethyl fumarate (DMF), utilized to therapeutically manage MS, has been shown to prevent caspase-1/GSDMD interaction rather than caspase-1 cleavage, finally inhibiting GSDMD-dependent pyroptosis. This evidence concerns the gene CASP1 and myeloid sarcoma.